Goldman Sachs upgrades Novo Nordisk (nvo) to Buy
Goldman Sachs upgraded Novo Nordisk from Neutral to Buy with a 740 Dkr price target, representing upside of 21%.
Novo Nordisk A/S, the world's largest maker of insulin, said Wednesday that it plans to expand its US headquarters in Princeton, New Jersey to accommodate future growth.